Essential Elements of 18F-FDG PET/CT Reporting
| Element | Description |
| Clinical history | Indication for study |
| Cancer type and site, if applicable | |
| Brief review of treatment history, if applicable | |
| Technique/procedure | Radiopharmaceutical name |
| Radiopharmaceutical dose/activity | |
| Route of radiopharmaceutical administration | |
| Uptake time (i.e., from radiopharmaceutical injection to imaging) | |
| Blood glucose level | |
| Ancillary medications administered, if applicable | |
| Precise body region scanned | |
| CT technique (including whether oral or intravenous contrast was used; if used, name and volume of agent) | |
| Comparison studies | Whether comparison was made with prior PET or PET/CT studies; include dates when available |
| Whether correlation was made with prior non-PET imaging studies (e.g., CT or MR imaging); include dates when available | |
| Findings | Location, size/extent, and intensity of sites of abnormal 18F-FDG uptake |
| Abnormal PET findings correlated with concurrent CT images or correlative imaging studies, if applicable | |
| Incidental PET findings | |
| Incidental CT findings | |
| Impression | Clear identification of study as normal vs. abnormal |
| Interpretation of findings, rather than just restatement of findings | |
| Succinct differential diagnosis provided, if applicable | |
| Recommendations for follow-up studies, if applicable | |
| Documentation of communication of urgent or emergent findings to referring physician or surrogate |